On June 10, 3SBio rose 5.32% in regular trading, trading at HK$16.4/share, with trading volume of approximately HK$300 million. The stock had previously touched its 52-week low of HK$15.50.

Multiple catalysts converged to drive the rebound. Chairman and CEO Lou Jing purchased 516,000 shares on June 8 at HK$15.2497 per share, totaling approximately HK$7.87 million, bringing his stake to 21.03%. Meanwhile, China launched a new round of national medical insurance catalog adjustments, drawing renewed market attention to the company's innovative pipeline.

The company's PD-1/VEGF bispecific antibody SSGJ-707, licensed to Pfizer with a US$1.5 billion upfront payment and US$6.05 billion total deal value, demonstrated strong Phase II clinical data with a confirmed ORR of 67.6% in PD-L1-positive NSCLC patients. Additionally, the board authorized directors to repurchase up to 10% of issued shares, providing further price support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)